Prof. Dr. Konrad Heintze is a specialist in pharmacology and toxicology. His career spans 12 years as professor at the medical faculty of the RWTH Aachen, 10 years in leading positions at the research departments of Byk Gulden (later Altana, now Nycomed) and Grünenthal. Later on he was head of the gastro-liver group at the German regulatory agency, BfArM, where he was responsible for centralised European applications and co-rapporteur in a number of cases. He has now been working as an independent consultant since 1994.
Selected References
Selected References
Prof. Dr. Werner Winter is professor of organic chemistry and up to now gives lectures at the University of Tübingen, Germany. He spent more than 12 years with Grünenthal and is a specialist for statistical data analyses and process control. He works as an expert for pharmaceutical quality for two German regulatory agencies (Federal Institute for Drugs and Medical devices, BfArM and Federal Office of Consumer Protection and Food Safety, BVL) and is involved in training courses for chemists and pharmacists on multivariate data analyses and design of experiments (DOE).
Selected References
Selected References
Dr. Helmut Buschmann is a senior management executive with over 17 years of international experience in drug discovery research and drug development in the pharmaceutical sector with particular strengths in identifying, evaluating and integrating pre-clinical projects and transfer to clinical phase. Some of the discovered drugs have reached clinical phase III or are registered (e.g. Tapentadol). He led or co-authored more than 90 publications in major scientific journals and is listed as inventor on more than 180 patent application families. As author and editor he has also published three books. As member of the “Research Director Group” (2004 – September 2008) inside the EFPIA (European Federation of Pharmaceutical Industries and Associations) he was participating in defining the Strategic Research Agenda (SRA) and creating together with the European Commission the Innovative Medicine Initiative (IMI). As a chemist he started his industrial career in 1992 at Grünenthal (Aachen) being responsible for chemical research (combinatorial and medicinal chemistry, process development and pilot plant) before he was joining Esteve (Barcelona) as a Research Director in 2002. In this position he managed a staff of 102 employees and was responsible for chemistry, pharmacology, toxicology, pharmacokinetic and intellectual property departments. In 2009 he joined Pharma Consulting Aachen.
Selected References
Selected References
Dr. Elmar Friderichs is a pharmacist and professional pharmacologist (DGPT). He worked more than 20 years as head of the Department of Pharmacology at Grünenthal Research, mainly involved in the development of opioid analgesics (Tramal®, Transtec®). Besides pain and inflammation pharmacology, he worked on neuroleptics, antidepressants, and tranquillizers, as well as on general CNS-pharmacology.
Selected References
Selected References
Dr. Maren Kops is a biotechnologist and specialised in molecular biology and virology during doctoral thesis (University of Freiburg, Germany) and postdoctoral research at Harvard Medical School, USA. She is additionally experienced with text processing and literature management. Since 2004 she has been working with Pharma Consulting Aachen.
Selected References
Selected References
Dr. Wolfgang Lintz is a chemist and worked for 32 years at Grünenthal. He became a specialist for pharmacokinetics and in the late sixties he established this new field of investigations at Grünenthal. As head of department he was responsible for preclinical and clinical pharmacokinetics. Since 2000 he has been working as consultant.
Selected References
Selected References
Dr. Theo Matthiesen is a veterinary pathologist and during his 30 year career in the pharmaceutical industry he specialised in experimental pathology and toxicology. During more than 15 years he was responsible for the entire package of preclinical-toxicological investigations during early research and development of pharmaceutical drug substances and drug products, including submissions to international regulatory authorities. In 2004 he joint Pharma Consulting Aachen.
Selected References
Selected References
Dr. Eve C. A. Morgenstern is a biologist experienced in research on various chemical entities, herbal extracts and other natural products for miscellaneous medicines, nutrition supplements and medical devices. As a professional pharmacologist (biologist in medicine) she worked successfully for more than 20 years in leading positions in several fields of pharmacological and toxicological research, quality assurance and regulatory affairs at the Institute for Pharmacological Research and the CRO Biopharm GmbH Berlin, later on at Nutri Pharma A/S, Copenhagen. Using her long international experience in interdisciplinary project management she is now providing advice and support in drug development and approval as an independent consultant.
Selected References
Selected References
Dr. Peter Kraahs is a pharmacist and an expert in drug product development. He has worked for 20 years in academic and industrial drug product development of new chemical entities,
Rx and OTC products, line extensions, generics, as well as food supplements, mainly in the field of oral solids. His main areas of focus are designed delivery products, multiple units, orodispersibles, taste masking, effervescent products, the improvement of drug solubility/ bioavailability, as well as drug product convenience and products for paediatric/ geriatric use. Further, he enjoys defining, implementing and continuously improving innovation management concepts in small and medium sized pharmaceutical companies.
Selected References
Rx and OTC products, line extensions, generics, as well as food supplements, mainly in the field of oral solids. His main areas of focus are designed delivery products, multiple units, orodispersibles, taste masking, effervescent products, the improvement of drug solubility/ bioavailability, as well as drug product convenience and products for paediatric/ geriatric use. Further, he enjoys defining, implementing and continuously improving innovation management concepts in small and medium sized pharmaceutical companies.
Selected References
